Orelabrutinib (ICP-022) 是一种强效、口服活性、不可逆的Bruton酪氨酸激酶 (BTK) 抑制剂。Orelabrutinib 具有用于 B 细胞恶性肿瘤的潜力。
货号:ajcx17004
CAS:1655504-04-3
分子式:C26H25N3O3
分子量:427.5
溶解度:DMSO: 250 mg/mL (584.80 mM)
纯度:98%
存储:Store at -20°C
库存:
现货Background:
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor. Orelabrutinib has the potential for B-cell malignancies treatment[1].
[1]. Wei Xu, et al. Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia. Blood (2019) 134 (Supplement_1): 4319.